Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Zentek Ltd - ZEN -- Ignore unavailable to you. Want to Upgrade?

To: Steakhouse who wrote (11610)	3/2/2021 10:37:44 AM
From: tturner	1 Recommendation Recommended By Steakhouse Respond to of 22641

steak, remember the change on the presentation. the mile-stone star changed... think it indicated the irritation study was done (star directly across from that line) The cyto study had yet to be done (no star across) From the discription, don't think the latest NR was THAT study. it was different. ISO 10993-5: Tests for in vitro Cytotoxicity This cytotoxicity test is performed according to the requirements described in Biological evaluation of medical devices – Part 5: Tests for in vitro cytotoxicity (ANSI/AAMI/ISO 10993-5). The test is designed to determine the biological response of mammalian cells exposed in vitro to extracts of the devices. The test article, positive and negative controls are extracted according to the method ISO 10993-12. The original extract is serially diluted and 5 concentrations are used for testing. L-929 cells are treated with extracts of the sample, reagent control, negative control or positive control. Triplicate plates are prepared for each treatment. The cells are incubated for 24 hours and observed microscopically for cytotoxic effects. Cultures are observed under microscopy and graded for reactivity using a 0 to 4 scale. Test article meets the requirement of the test when results are less than a grade of 2. A report will be issued 4-6 weeks after the receipt of the test substance.